Abstract | BACKGROUND: Once a diagnosis of left ventricular thrombus has been established, the classical attitude consists in the administration of unfractionated heparin relayed by oral anticoagulation therapy. However, the use of unfractionated heparins in this indication was only assessed in an open, non-randomized study with no control group, including 23 patients. On the other hand, although low molecular weight heparins are routinely used in some departments, there are no studies available concerning these agents in this indication. The aim of this study was to evaluate the feasibility of low molecular weight heparin therapy in patients with left ventricular thrombi. METHODS: The study was a prospective, non-randomized, open-label trial. All patients with a new left ventricular thrombus diagnosed between September 2000 and September 2003 received enoxaparine 100 IU/kg twice daily for a mean duration of 13 days. A relay treatment with fluindione was initiated on day 5. The left ventricular thrombus outcome was followed for 3 weeks by bi-weekly transthoracic echocardiography. RESULTS: CONCLUSION: This preliminary study suggests that low molecular weight heparins are well tolerated and efficient in terms of left ventricular thrombi disappearance or size reduction.
|
Authors | Philippe Meurin, Jean Yves Tabet, Nathalie Renaud, Hélène Weber, Anne Grosdemouge, Claude Bourmayan, Ahmed Ben Driss |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 98
Issue 2
Pg. 319-23
(Feb 15 2005)
ISSN: 0167-5273 [Print] Netherlands |
PMID | 15686785
(Publication Type: Clinical Trial, Journal Article, Multicenter Study)
|
Chemical References |
- Anticoagulants
- Enoxaparin
|
Topics |
- Anticoagulants
(administration & dosage, therapeutic use)
- Enoxaparin
(administration & dosage, therapeutic use)
- Female
- Heart Diseases
(diagnostic imaging, drug therapy)
- Heart Ventricles
- Humans
- Male
- Middle Aged
- Prospective Studies
- Thrombosis
(diagnostic imaging, drug therapy)
- Ultrasonography
|